Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026
Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Fineline Cube Jul 2, 2026
Company Drug

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Fineline Cube Jul 2, 2026
Company Drug

Ascletis Pharma’s COVID-19 Drug Candidate ASC11 Accepted for Review by NMPA

Fineline Cube Nov 30, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its Investigational New Drug (IND) filing...

Company Deals

Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline

Fineline Cube Nov 30, 2022

China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...

Company Deals

Fosun Pharma Weighs Sale of India’s Gland Pharma Amid Market Interest

Fineline Cube Nov 30, 2022

Shanghai Fosun Pharmaceutical Group Co. (HKG: 2196, SHA: 600196) is reportedly considering the sale of...

Company Deals

Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million

Fineline Cube Nov 30, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd...

Company Drug

Luye Pharma Initiates Phase II Study for LY 03014 in China

Fineline Cube Nov 30, 2022

China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...

Policy / Regulatory

China’s Drug-Eluting Stent Procurement Results Announced

Fineline Cube Nov 30, 2022

The national high-value medical consumables alliance procurement office has released the results of the successive...

Company Deals

Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement

Fineline Cube Nov 30, 2022

China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities...

Company Deals

Frontier Biotechnologies Partners with CASAPC for AIDS Prevention in China

Fineline Cube Nov 30, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced a collaboration agreement with the Chinese Association...

Company Drug

Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang

Fineline Cube Nov 30, 2022

Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...

Company Deals

JancsiTech Raises Tens of Millions in Angel Round Led by Yuanbio Venture Capital

Fineline Cube Nov 30, 2022

JancsiTech, a precision nuclear medicine specialist based in Shenzhen, has reportedly raised “tens of millions”...

Company Drug

FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment

Fineline Cube Nov 30, 2022

US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA)...

Company

Sino Biological to Invest RMB 1 Billion in Beijing Bio-Pharmaceutical Park

Fineline Cube Nov 30, 2022

Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140...

Company Drug

Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment

Fineline Cube Nov 29, 2022

China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine...

R&D

Hong Kong Researchers Identify New Target for Epilepsy Treatment

Fineline Cube Nov 29, 2022

Researchers at the University of Hong Kong have published the results of a study that...

Company Drug

Hope Medicine Gains Global Approval for Phase II Trial of HMI-115

Fineline Cube Nov 29, 2022

China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...

Company Deals

Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline

Fineline Cube Nov 29, 2022

Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...

Policy / Regulatory

NMPA Launches Electronic Certificates for API and Pharmaceutical Product Exports

Fineline Cube Nov 29, 2022

The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two...

Company Deals

I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies

Fineline Cube Nov 29, 2022

China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to...

Company Deals

Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round

Fineline Cube Nov 29, 2022

China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...

Company

Alibaba Health Reports 22.9% Revenue Growth in H1 2022

Fineline Cube Nov 29, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the...

Posts pagination

1 … 617 618 619 … 689

Recent updates

  • Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval
  • Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy
  • Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile
  • Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics
  • Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Company Drug

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.